Avagacestat, also known as BMS-708163, is an oral GSI designed for selective inhibition of Aβ synthesis currently in development for the treatment of mild to moderate and predementia AD. In addition to the desired effect on Aβ synthesis, GSIs affect Notch processing, which is thought to mediate some toxic adverse effects reported with this drug class.
Gamma-secretase Inhibitors Related Products:
RO4929097; Semagacestat; Dibenzazepine; LY-411575; Crenigacestat; DAPT (GSI-IX)